Abstract The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still undetermined. In particular, the recommended target of hematocrit (Hct) <0.45 has been recently questioned and alkylating drugs are still used for elderly patients. We revised, according to WHO criteria, 300 PV diagnosis and evaluated the impact on clinical outcome of median Hct and of the strategy to administer anti-thrombotic prophylaxis and to avoid alkylating chemotherapy in almost all patients. Of 226 patients with WHO-confirmed diagnosis (median age 66), 91.3% survived at the median follow-up of 5.84 years and 77.5% are projected alive at 13 years. Eighteen percent had major thrombosis and 2.7% acute myeloid leukemia. Twenty-two percent of patients maintained an Hct <0.45: their overall and thrombosis-free survival are similar to those of patients with a 0.45-0.48 value. Conversely, an Hct >0.48 and a "high thrombotic risk" according to ECLAP criteria were both significantly associated to shorter survival and higher thrombosis risk. Chemotherapy reduced thrombotic events without affecting survival. Our study revealed suboptimal compliance to published guidelines. However, in our casistic characterized by wide use of anti-platelet-and avoidance of alkylating drugs, patients' survival, although analyzed retrospectively, seemed to have improved compared to old literature data. The optimal Hct target was not clearly defined, although a value <0.48 looks highly advisable.
Introduction
Polycythemia vera (PV) is the most common chronic myeloproliferative neoplasm, with an annual incidence of 2.3 per 100,000 [1, 2] , a reported median survival of 10-15 years [3] [4] [5] [6] and an overall mortality of 3.5 per 100 person/year [5] . Thrombotic complications are the main cause of morbidity and mortality, occurring in more than one third of patients and causing 35-45% of deaths [5, 6] . Other possible adverse events are the evolution into secondary myelofibrosis (MF) or acute myeloid leukemia (AML) occurring in 10-15% [4, [6] [7] [8] and 2-15% [4, [8] [9] [10] [11] [12] [13] [14] [15] [16] of patients, respectively, depending on treatments and with increased incidence with long-standing disease.
Diagnostic criteria have been revised many times since their first publication by the Polycythemia Vera Study Group in 1975 [17, 18] . Recently, the World Health Organization (WHO) proposed new criteria, in consideration of the discovery of JAK2 mutation role in PV [19, 20] . However, before the discovery of JAK2 mutations [21] [22] [23] [24] [25] , differential diagnosis between PV and secondary erythrocytosis was not always immediate and it is unclear how previous WHO diagnostic recommendations have been actually followed in general practice, outside of clinical trials.
Current therapy guidelines recommend phlebotomy as firstline treatment, in order to maintain the hematocrit (Hct) value below 0.45 and prevent cardiovascular accidents [18] . Lowdose acetyl-salicylic acid (ASA) has been recommended too, unless contraindicated, in order to reduce thrombotic risk and mortality; conversely cytoreductive therapy is recommended only in the presence of poor tolerance to phlebotomy, symptomatic or progressive splenomegaly or evidence of high thrombotic risk or disease progression [18, [26] [27] [28] [29] .
In spite of well-established therapeutic guidelines, some doubts still remain about the optimal management of PV patients. Indeed, a recent European survey on a very large casistics (ECLAP study) questioned the actual role of a low (<0.45) Hct value in reducing the thrombotic risk [29, 30] . Moreover, the same study evidenced that even in the setting of a clinical study, about 60% of patients did not reach or maintain the recommended Hct value [30] . Therefore, it is unclear how the strict requirement of intensive Hct reduction has been actually satisfied outside of clinical trials. For chemotherapy-requiring patients, hydroxyurea (HU) is generally recommended as first-line agent because of its unproven leukemogenicity [28] . However some alkylating agents like pipobroman and busulfan are still used, particularly in elderly patients [26] .
In this study, we performed a retrospective analysis on 300 patients with a PV diagnosis, referred to a single blood bank for phlebotomy. The primary objectives of the study were: (1) to evaluate in our casistics the controversial role of Hct value in survival and thrombosis prevention; (2) to verify whether the strategy for near all patients of anti-thrombotic prophylaxis and avoidance of alkylating chemotherapy might have improved survival and reduced AML and major thrombosis incidence, compared to literature data. As secondary objectives, we verified in our patients the actual adherence to published diagnostic and therapeutic guidelines in routine management of PV and the prognostic role of some known risk factors.
Methods
The present analysis is a retrospective study based on the database of polycythemic patients of S. Giovanni Battista Hospital transfusion center in Turin, Italy. Patients were followed in three different hematological institutions but all of them referred to this single transfusion center for phlebotomy. Patients' data were cumulatively evaluated anonymously, in agreement to local ethical rules. Only patients with a diagnosis of PV made from January 1, 1995 to March 31, 2008 were included. Each diagnosis was revised to include in the study only the cases that fully satisfied either 2001 or 2007 WHO diagnostic criteria for PV. Data files were reviewed before inclusion in the present analysis and the times of observation were censored on December 31, 2008.
Primary end-points were overall survival (OS), defined as the time from diagnosis to death for any cause or last follow-up alive, time to occurrence of total thrombosis (TTT) and time to occurrence of major thrombosis (TMT). Major thrombotic events comprehended ischemic stroke, acute myocardial infarction, deep venous thrombosis and pulmonary embolism. Total thrombosis included all major events plus transient ischemic attacks, peripheral arterial thrombosis and superficial thrombophlebitis. Secondary end-points included the incidence and time to development of AML, solid tumors or secondary MF.
For each patient, the following parameters at diagnosis were evaluated: age; presence of cardiovascular risk factors such us hypertension, diabetes, cigarette smoking, dyslipidemia; history of thrombosis or bleeding. These parameters were used to define the thrombotic risk according to the recent definition by Finazzi and Barbui based on ECLAP data [28, 29] (32, 33) c Percent of chemotherapy-treated patients; some patients received more than one treatment for platelet counts were 400×10 9 /l, corresponding to the normal upper range, and 600×10 9 /l, the thrombocytosis threshold previously used by WHO guidelines for the diagnosis of essential thrombocythemia [31] . A leukocyte cutoff value of 15×10 9 /l was chosen, since it has been previously reported to be prognostically relevant in terms of thrombosis-free survival [32] .
Statistical methods
Patients' characteristics were compared using the Pearson χ 2 test for discrete variables and the Mann-Whitney test for continuous variables. OS, TTT, TMT, time to development of AML, solid tumors or secondary MF were analyzed by the Kaplan-Meier method, comparing the two arms by the log-rank test and calculating 95% confidence intervals (CIs). Univariate and multivariate analyses were performed using the Cox model and the following variables were considered: gender (male vs. female), age at diagnosis (>65 vs. <65 years), Hct during follow-up, platelet count at diagnosis and during followup (<400×10 9 /l vs. 400-600×10 9 /l vs. >600×10 9 /l), white blood cell (WBC) count at diagnosis and during follow-up (<15×10 9 /l vs. >15×10 9 /l), thrombotic risk according to ECLAP study (high vs. low-intermediate), prior thrombosis (yes vs. no), cytoreductive treatment (yes vs. no), cardiovascular risk factors at diagnosis (yes vs. no). Since some variables were time-varying, depending on single outcome events (thrombotic risk in OS, Hct, and cytoreductive treatment in TTT and TMT), their impact on OS, TTT, and TMT was then studied by three different multivariate Cox time-dependent models. The cumulative incidence of AML, MF, and tumors other than AML was determined using the Fine and Gray competing risk regression model. All reported p values are two sided at the conventional 5% significance level. Data were analyzed as of March 2009 by SPSS 17.0 (SPSS Inc., USA).
Results
Among the whole casistics of 300 patients, 226 satisfied either 2001 or 2007 WHO diagnostic criteria for PV and underwent further evaluation of clinical outcome.
The main clinical features of the cohort are shown in Table 1 . Median follow-up was equal to 5.84 years (range 0.76-13.78) and only three patients were lost to follow-up. Known risk factors at diagnosis comprehended history of previous thrombosis in 55 (24%; arterial thrombosis constituting 85% and venous thrombosis 15% of these thrombotic events) and concomitant cardiovascular risk factors in 137 (61%) patients. According to the thrombotic risk stratification, 39 patients were in the low-risk group, 29 in the intermediate one and 158 (70%) in the high-risk group.
All patients received phlebotomy at least in the first month from diagnosis. Seventy-five patients proceeded with phlebotomy only, whereas 151 also received a cytoreductive treatment for at least 6 months (median 4 years). The main cytoreductive treatment was hydroxyurea, used as first-line therapy by 147 (97%) chemotherapy-treated patients. In particular, HU was the only cytoreductive agent for 126 patients (83%), whereas other patients received more than one cytoreductive treatment. Other drugs included pipobroman (19 patients), busulfan (five patients), and alpha interferon (two patients): they were used in the case of intolerance or suboptimal response to HU. Almost all patients (98.2%) received either anti-platelet (209) and/or anticoagulant (34) therapy.
Median Hct during follow-up was kept at the recommended value below 0.45 in 46/211 evaluable patients (22%). Sixty-two percent of patients maintained a median Hct value between 0.45 and 0.48, whereas in 16% the median Hct value was >0.48. Regarding WBC count, a median value above 15×10 9 /l was observed in 23 patients (11%). A median platelet value under 400×10 9 /l was maintained in 110 patients (52%), whereas values between 400×10 9 /l and 600×10 9 /l, or above 600×10 9 /l were observed in 74 patients (35%) and 27 patients (13%), respectively.
During follow-up, 25 patients (11%) died. Survival rate was 91.3% at the median follow-up of 5.8 years and is projected to 77% at the longest follow-up of 13.8 years (Fig. 1a) . Cardiovascular and thrombotic mortality accounted for 32% of all deaths, while hematological transformation and solid tumors accounted for 24% of deaths each. Overall survival was negatively influenced by median Hct over 0.48 (p=0.001; Table 2 and Fig. 1b) and "high risk" score according to thrombotic risk stratification (p=0.038) ( Table 2 and Fig. 1c) , whereas sex had no prognostic value (Table 2) . At multivariate OS analysis, the impact of median Hct over 0.48 and of high thrombotic risk on total mortality was confirmed, with a hazard ratio (HR) of 3.41 (p=0.004) and 1.56 (p=0.050), respectively (Table 3 ). However, due to the low number of dead patients no statistically significant difference was found in the causes of death according to median Ht value.
Thrombotic events occurred in 58 patients (25.7%) during follow-up, after a median time of 58 months (4.8 years). Nineteen percent of patients had a major thrombotic event. The main prognostic factors affecting time to thrombotic events were age over 65 (TTT p<0.001, TMT p=0.001), Hct over 0.48 (TTT p=0.020, TMT p= 0.002), and high thrombotic risk (TTT p=0.028; Table 4 , Fig. 2 ). On the contrary, cytoreductive treatment resulted in a protective agent (TTT p<0.001, TMT p<0.001) ( Table 4 , Fig. 2) . At multivariate analysis, major thrombosis were significantly associated with Hct over 0.48 (p=0.011) and inversely related to cytoreductive treatment (p<0.001; Table 3 ). Lower Hct values (≤0.45) did not significantly discriminate patients in terms of survival and time to thrombosis.
Follow-up WBC and PLT counts did not affect either overall or thrombosis-free survival.
Seventeen and five episodes of major and minor bleeding were observed, respectively. Sixteen events occurred during anti-platelet therapy but only four caused its Leukemic evolution occurred in six patients (2.7%), four of whom had received chemotherapy, after a median time of 7 years, with a cumulative incidence of 4.5% at 10 years. Secondary MF and neoplasia other than AML were observed in 11 (4.9%) and 15 (6.6%) patients, respectively. Evolution to MF occurred after a median time of 7 years and had a cumulative incidence of 7.95% at 10 years. Chemotherapy did not significantly affect either the hematological transformation or the occurrence of total malignancies (Table 5) . Evolution in MF, at univariate analysis, was associated with high Hct levels (over 0.48; p=0.007; Table 5 ).
Discussion
The present study was aimed to evaluate the clinical management and outcome of PV patients in the past 14 years in our city, outside of clinical trials. In particular, we wished to ascertain, although retrospectively, a possible positive role on survival of the choice to give antithrombotic prophylaxis and to avoid alkylating drugs in 98% and 89% of patients, respectively. We also tried to ascertain the clinical impact of median Hct value during the follow-up. Considering the reported PV incidence [1, 2] , our casistics probably includes more than 50% of PV cases occurred during those years in the city of Turin. Follow-up was fairly accurate, as three patients only were lost and, moreover, all evaluated patients had at least three complete blood counts performed/year. About 25% of cases referred to our transfusion center for phlebotomy had a PV diagnosis that did not satisfy all WHO diagnostic criteria. Although in many of these cases the diagnosis might have been correct, according to their further clinical outcome, they have been excluded from further evaluations, wishing to restrict prognostic considerations to patients with a doubtless PV diagnosis. In all cases, the unconfirmed diagnosis was made before the analysis of JAK2 status entered the clinical practice. Conversely, 94% of patients with a PV diagnosis tested in the past 3 years for JAK2 status evidenced the V617F mutation, in agreement to the more recent literature data [25] . These observations illustrate how PV diagnosis might be difficult before the advent of the molecular test and confirm the great impact of JAK2 analysis in improving the diagnostic accuracy.
The median age at diagnosis of our patients (66 years) was relatively advanced, slightly higher than the one previously reported for a large population of unselected Italian PV patients [6] . This certainly contributed to the high proportion (70%) of patients in the group of high thrombotic risk. In spite of these unfavorable prognostic features, the overall survival (91% at the median follow-up time of 5.84 years) compares favorably to that reported in many other studies [3] [4] [5] [6] . Although we did not perform a prospective, randomized study and the median follow-up is shorter than 10 years, the wide use in our patients of lowdose ASA and the strong limitation of alkylating cytotoxic therapy may have contributed to this more favorable outcome and to an incidence of leukemic transformation in the lowest range of values reported in literature [4, [6] [7] [8] . Indeed, a French randomized study with very long followup has recently demonstrated a lower incidence of leukemic evolution and improved survival with the use of hydroxyurea compared to pipobroman [32] .
Low-dose ASA might have also contributed to the relatively low incidence of major thrombosis (18%), in the lower range of literature data [6, 27] , without increasing hemorrhagic complications compared to published observations [33] . Nevertheless, the high thrombotic risk according to Finazzi et al. [28, 29] confirmed its negative prognostic impact in terms of overall and thrombosis-free survival in both univariate and multivariate analysis.
Differently from what is reported in another study [34] , WBC value during follow-up did not significantly affect survival and thrombotic complications. However, few patients (22:10.2%) maintained a value above the reported threshold of 15 ×10 9 /l: this may explain the lack of significant difference in thrombosis-free survival. Chemotherapy given before the occurrence of a thrombotic event significantly prolonged the freedom from major thrombosis but did not affect overall survival, in agreement to some previous reports [14, 16, 28] .
Regarding Hct target, the need of keeping a value<0.45, as recommended by guidelines [18, 29, 35] has been recently questioned by the ECLAP study [30] . Unfortu- nately, few patients (22% only) in our survey were actually maintained at an Hct value<0.45, this suggesting the difficulties for patients and/or physicians to comply with published guidelines, in agreement to other reports [30, 36] . Although this group of patients had a favorable outcome, no significant differences could be detected in terms of overall or thrombosis-free survival compared to the larger group of patients who maintained median Hct values in the range of 0.45 -0.48. Conversely, the few patients (16%) with a poor control of erythrocytosis (median Hct value> 0.48) had a significantly worst outcome in terms of both overall survival and time to major thrombosis, both by univariate and multivariate analysis.
In conclusion, although our study is retrospective and the casistic is not very large, the results obtained on unselected PV patients receiving routine care are in agreement to the already reported positive roles of antiplatelet therapy and of hydroxyurea as a cytoreductive drug. The role of JAK2 status analysis in improving the diagnostic accuracy has been also confirmed, as well as the negative impact of belonging to the high thrombotic risk category. Other known risk factors, such as leukocytosis and prior thrombosis could not be confirmed in our casistic, probably because of the relatively limited number of patients. Regarding one of the most controversial point in the last years, the Hct value to be pursued, we believe on the basis of our results that a good control of erythrocytosis, with an Hct value below 0.48 may be advisable, although definitive conclusions on the optimal value have not been reached. A randomized study is ongoing in Italy comparing different Hct targets and hopefully should provide more sound information about the optimal value to be achieved. 
